AbbVie is going for it in cystic fibrosis. But why are they buying the weak Galapagos portfolio in a $245M deal?
AbbVie took a hard look at some weak data for Galapagos’ $GLPG double and triple for cystic fibrosis — and decided to buy the lot.
We already knew that the Phase II study of the C2 corrector GLPG2737 combined with Orkambi didn’t work all that well. Now new data from Galapagos help prove that adding it to their GLPG2451 and GLPG2222 drugs did nothing at all to improve results.
The double alone produced “a mean increase in ppFEV1 of approximately 3%.” The triple did no better.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.